Retroperitoneal cystic lymphangioma.

An interesting and rare differential diagnosis for a retroperitoneal cystic mass is cystic lymphangioma. A case of a patient presenting with a multicystic mass in the retroperitoneum that was identified as a cystic lymphangioma is reported. These tumours are commonly confused with other cystic masses in the retroperitoneum.

Primary hydatid disease of the soft tissue.

Human hydatid disease is caused by the larval form of the tapeworm genus Echinococcus. The ova hatch in the small intestine, penetrate the intestinal wall, pass through the portal vein into the liver, lungs, and other tissues, and develop into a hydatid cyst. Hydatid disease is endemic in many parts of the world; in the Mediterranean Countries, the Middle and Far East and South America. Soft tissue hydatid disease without the liver and the lung involvement occurs in 2.3% of patients reported from endemic areas. Hydatid disease should be considered in the differential diagnosis of all cystic masses in all anatomic locations especially in endemic areas.

The effect of L-thyroxine replacement therapy on lipid based cardiovascular risk in subclinical hypothyroidism.

The aim of our study was to assess the changes in serum lipid profiles after replacement therapy with L-T4 in patients with subclinical hypothyroidism (SCH), and to see whether there is an improvement in dyslipidemia based cardiovascular risk. Thirty non-smoker pre-menopausal women with newly diagnosed SCH (TSH between 4 and 10 microIU/ml) were involved in our study; twenty-six euthyroid healthy subjects were used as control group. TSH, free T3 (FT3), free T4 (FT4), total cholesterol (TC), triglyceride (TG), HDL cholesterol (HDL-C) and LDL cholesterol (LDL-C) levels were measured before and after 6 months of L-T4 (50-100 microg/ day) therapy. TSH levels were targeted as < 2.0 microIU/ml. LDL-C was calculated using the Friedewald formula, while the cardiovascular risk was assessed with the TC/HDL-C ratio. Pre-treatment serum TC and LDL-C concentrations in SCH patients were significantly higher than those of euthyroid subjects (199.8 +/- 22.2 vs 181.5 +/- 24.6 mg/dl, p < 0.01; 146.3 +/- 26.1 vs 124.8 +/- 12 mg/dl, p < 0.001, respectively). TC, LDL-C levels and the TC/HDL-C ratio were reduced significantly after 6-month replacement therapy (-21.1 +/- 34.4 mg/dl or -10.5%, p < 0.01; -21.5 +/- 30.3 mg/dl or -14.7%, p < 0.001, respectively; and TC/HDL-C from 4.8 +/- 0.6 to 4.1 +/- 0.5 mg/dl, p < 0.01), while body mass index (BMI) values did not change. In conclusion, even mild elevations of TSH are associated with changes in lipid profile significant enough to raise the cardiovascular risk ratio, and these changes are corrected once the patients have been rendered euthyroid.